Vincent Meiffredy
Overview
Explore the profile of Vincent Meiffredy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mchantaf G, Cheret A, Melard A, Essat A, Gardiennet E, Bauer R, et al.
J Virus Erad
. 2024 Jan;
9(4):100357.
PMID: 38188640
Background: Understanding factors affecting the size and the evolution of the HIV reservoir is essential for the development of curative strategies. This study aimed to assess the impact of antiretroviral...
2.
Cheret A, Bauer R, Meiffredy V, Lopez P, Ajana F, Lacombe K, et al.
J Antimicrob Chemother
. 2022 Jun;
77(9):2506-2515.
PMID: 35762503
Background: Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown. We hypothesized that once-daily dolutegravir/tenofovir/emtricitabine could...
3.
Mariaggi A, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, et al.
J Antimicrob Chemother
. 2022 Feb;
77(3):735-739.
PMID: 35195692
Background: Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral...
4.
Durier C, Mercier-Delarue S, Verdiere N, Meiffredy V, Matheron S, Samri A, et al.
AIDS
. 2021 Dec;
36(2):319-321.
PMID: 34934023
No abstract available.
5.
Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, et al.
AIDS
. 2018 Aug;
32(16):2291-2299.
PMID: 30096071
Objectives: The objective of this study is to investigate immunogenicity and safety of the yellow fever vaccine (YFV) in HIV-infected (HIV+) patients with high CD4 T-cell counts. Design: In this...
6.
Mercier-Delarue S, Durier C, Verdiere N, Poveda J, Meiffredy V, Fernandez Garcia M, et al.
PLoS One
. 2017 Jun;
12(5):e0177882.
PMID: 28562615
Given the possibility of yellow fever virus reintroduction in epidemiologically receptive geographic areas, the risk of vaccine supply disruption is a serious issue. New strategies to reduce the doses of...
7.
Le Corre N, Thibault F, Pouteil Noble C, Meiffredy V, Daoud S, Cahen R, et al.
Vaccine
. 2012 Oct;
30(52):7522-8.
PMID: 23103195
Background: Enhancing vaccine immunogenicity in kidney transplant recipients, particularly against influenza, is required since the immunosuppression used to prevent graft rejection limits vaccine immunogenicity. We therefore investigated the immunogenicity and...
8.
Bouldouyre M, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, et al.
J Acquir Immune Defic Syndr
. 2009 Oct;
52(5):531-7.
PMID: 19855285
Background: Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated. Methods: Well-suppressed patients on HAART were randomized to continuous (CT)...
9.
Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffredy V, Venet A, et al.
AIDS Res Hum Retroviruses
. 2007 Oct;
23(9):1105-13.
PMID: 17919105
HIV-specific T cell responses play a critical role in the control of infection. We evaluated the impact of immune-based interventions in patients first treated during primary HIV-1 infection (PHI). Forty-three...
10.
Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, et al.
AIDS
. 2006 Apr;
20(7):1039-49.
PMID: 16603857
Background: HIV-1 lipopeptides have been developed by the French National Agency for AIDS Research (ANRS) for use as candidate vaccine against HIV since 1994. Between 1996 and 2005, four different...